N-desethyloxybutynin (BioDeep_00000492000)

   


代谢物信息卡片


N-desethyloxybutynin

化学式: C20H27NO3 (329.1991)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCNCC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
InChI: InChI=1S/C20H27NO3/c1-2-21-15-9-10-16-24-19(22)20(23,17-11-5-3-6-12-17)18-13-7-4-8-14-18/h3,5-6,11-12,18,21,23H,2,4,7-8,13-16H2,1H3

描述信息

D000890 - Anti-Infective Agents > D000892 - Anti-Infective Agents, Urinary > D008333 - Mandelic Acids

同义名列表

1 个代谢物同义名

N-desethyloxybutynin



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Melanie Kretschmar, Ahmed Abbas Suleiman, Petra Krause, Uwe Albrecht, Raimund Stein, Peter Rubenwolf, Uwe Fuhr, Max Taubert. A Population Pharmacokinetic Model of (R)- and (S-) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers. Journal of clinical pharmacology. 2021 07; 61(7):961-971. doi: 10.1002/jcph.1809. [PMID: 33368382]
  • Zhixin Miao, Melvin Tan, Edward Wells, Steve Unger. The impact of hemolysis on stability of N-desethyloxybutynin in human plasma. Bioanalysis. 2019 Dec; 11(23):2133-2144. doi: 10.4155/bio-2019-0160. [PMID: 31729241]
  • Yongzhi Tian, Yongqing Wen, Jinghan Sun, Longshan Zhao, Zhili Xiong, Feng Qin. Simultaneous quantification of oxybutynin and its active metabolite N-desethyl oxybutynin in rat plasma by ultra-high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study of oxybutynin transdermal patch. Biomedical chromatography : BMC. 2019 Apr; 33(4):e4456. doi: 10.1002/bmc.4456. [PMID: 30536598]
  • Primal Sharma, Daxesh P Patel, Mallika Sanyal, Swati Guttikar, Pranav S Shrivastav. Parallel achiral-chiral determination of oxybutynin, N-desethyl oxybutynin and their enantiomers in human plasma by LC-MS/MS to support a bioequivalence trial. Journal of pharmaceutical and biomedical analysis. 2014 Jan; 88(?):81-91. doi: 10.1016/j.jpba.2013.08.032. [PMID: 24036364]
  • Primal Sharma, Daxesh P Patel, Mallika Sanyal, Hiren Berawala, Swati Guttikar, Pranav S Shrivastav. Simultaneous analysis of oxybutynin and its active metabolite N-desethyl oxybutynin in human plasma by stable isotope dilution LC-MS/MS to support a bioequivalence study. Journal of pharmaceutical and biomedical analysis. 2013 Oct; 84(?):244-55. doi: 10.1016/j.jpba.2013.06.024. [PMID: 23867086]
  • Roger R Dmochowski, Diane K Newman, Peter K Sand, Delbert C Rudy, Kim E Caramelli, Heather Thomas, Gary Hoel. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Clinical drug investigation. 2011; 31(8):559-571. doi: 10.2165/11588990-000000000-00000. [PMID: 21721591]
  • Haruhi Mizushima, Kazuya Kinoshita, Koji Abe, Hitoshi Ishizuka, Yasuhiko Yamada. Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats. Biological & pharmaceutical bulletin. 2007 May; 30(5):955-62. doi: 10.1248/bpb.30.955. [PMID: 17473442]
  • Joseph L Reiz, Paulette Salem, Andrew C Darke. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. Journal of clinical pharmacology. 2007 Mar; 47(3):351-7. doi: 10.1177/0091270006297226. [PMID: 17322147]
  • H Mizushima, K Takanaka, K Abe, I Fukazawa, H Ishizuka. Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica; the fate of foreign compounds in biological systems. 2007 Jan; 37(1):59-73. doi: 10.1080/00498250600976088. [PMID: 17178634]
  • Tomomi Oki, Ayako Toma-Okura, Shizuo Yamada. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion. The Journal of pharmacology and experimental therapeutics. 2006 Mar; 316(3):1137-45. doi: 10.1124/jpet.105.094508. [PMID: 16282521]
  • G Willy Davila. Transdermal oxybutynin in the treatment of overactive bladder. Clinical interventions in aging. 2006; 1(2):99-105. doi: 10.2147/ciia.2006.1.2.99. [PMID: 18044106]
  • Tomomi Oki, Shuichi Sato, Keiji Miyata, Shizuo Yamada. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. British journal of pharmacology. 2005 May; 145(2):219-27. doi: 10.1038/sj.bjp.0706184. [PMID: 15753946]
  • Tomomi Oki, Akihiro Kawashima, Masayuki Uchida, Shizuo Yamada. In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin. Life sciences. 2005 Apr; 76(21):2445-56. doi: 10.1016/j.lfs.2004.11.013. [PMID: 15763076]
  • M Asif A Siddiqui, Caroline M Perry, Lesley J Scott. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs. 2004; 64(8):885-912. doi: 10.2165/00003495-200464080-00011. [PMID: 15059046]
  • Rodney A Appell, Michael B Chancellor, R Howard Zobrist, Heather Thomas, Steven W Sanders. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clinic proceedings. 2003 Jun; 78(6):696-702. doi: 10.4065/78.6.696. [PMID: 12934778]
  • Hohyun Kim, Sang Beom Han. Sensitive determination of oxybutynin and desethyloxybutynin in dog plasma by LC-ESI/MS/MS. Journal of pharmaceutical and biomedical analysis. 2003 Feb; 31(2):341-9. doi: 10.1016/s0731-7085(02)00644-1. [PMID: 12609673]
  • Lynne M Bang, Stephanie E Easthope, Caroline M Perry. Transdermal oxybutynin: for overactive bladder. Drugs & aging. 2003; 20(11):857-64. doi: 10.2165/00002512-200320110-00007. [PMID: 12964892]
  • Akimasa Shibukaw, Yuki Yoshikawa, Tomoko Kimura, Yukihiro Kuroda, Terumichi Nakagawa, Irving W Wainer. Binding study of desethyloxybutynin using high-performance frontal analysis method. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2002 Feb; 768(1):189-97. doi: 10.1016/s0378-4347(01)00499-6. [PMID: 11939552]
  • Kari Lehtoranta, Hanna Tainio, Eeva Lukkari-Lax, Tiina Hakonen, Teuvo L J Tammela. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scandinavian journal of urology and nephrology. 2002 Feb; 36(1):18-24. doi: 10.1080/003655902317259319. [PMID: 12002352]
  • S M Di Stasi, A Giannantoni, P Navarra, G Capelli, L Storti, M Porena, R L Stephen. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. The Journal of urology. 2001 Dec; 166(6):2232-6. doi: 10.1016/s0022-5347(05)65540-1. [PMID: 11696741]
  • R H Zobrist, B Schmid, A Feick, D Quan, S W Sanders. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharmaceutical research. 2001 Jul; 18(7):1029-34. doi: 10.1023/a:1010956832113. [PMID: 11496941]
  • A Schröder, R M Levin, B A Kogan, A K Das, F Kay, A Mahashabde. Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder. Urology. 2000 Dec; 56(6):1063-7. doi: 10.1016/s0090-4295(00)00782-2. [PMID: 11113769]
  • S K Gupta, G Sathyan. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. Journal of clinical pharmacology. 1999 Mar; 39(3):289-96. doi: . [PMID: 10073329]
  • M Yaïch, M Popon, Y Médard, E J Aigrain. In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics. 1998 Oct; 8(5):449-51. doi: 10.1097/00008571-199810000-00010. [PMID: 9825837]
  • E Lukkari, K Aranko, A Juhakoski, T Hakonen, P J Neuvonen. Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet. Pharmacology & toxicology. 1997 Jul; 81(1):31-4. doi: 10.1111/j.1600-0773.1997.tb00027.x. [PMID: 9258982]
  • E Lukkari, A Juhakoski, K Aranko, P J Neuvonen. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. European journal of clinical pharmacology. 1997; 52(5):403-6. doi: 10.1007/s002280050309. [PMID: 9272412]
  • C G Nilsson, E Lukkari, M Haarala, A Kivelä, T Hakonen, P Kiilholma. Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. Neurourology and urodynamics. 1997; 16(6):533-42. doi: 10.1002/(sici)1520-6777(1997)16:6<533::aid-nau3>3.0.co;2-f. [PMID: 9353802]
  • K M Hughes, J C Lang, R Lazare, D Gordon, S L Stanton, J Malone-Lee, M Geraint. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica; the fate of foreign compounds in biological systems. 1992 Jul; 22(7):859-69. doi: 10.3109/00498259209053145. [PMID: 1455904]